The incidence of breast cancer is increasing in the most part of the world and the rate of advanced cases is high. In the management of breast cancer, anthracycline-based chemotherapy regimens remain standard adjuvant or fi rst-line palliative treatment. Patients with metastatic breast cancer (MBC) are frequently exposed to high cumulative doses of anthracyclines and are at risk of resistance and cardiotoxicity. The second line treatment is indefi nited and treatment options are limited. Cisplatin or carboplatin are active in patients with metastatic breast cancer, the combination of Cisplatinum could be an effective therapeutic alternative to the resistance after anthracycline-containing regimens.